How do you approach adjuvant chemotherapy in an adult with localized osteosarcoma who demonstrates 50–90% tumor necrosis on surgical pathology following neoadjuvant doxorubicin and cisplatin?  

There remains controversy regarding this. The largest trial to compare MAP (continuation of induction therapy into consolidation therapy) vs MAP-IE (addition of IE to conventional MAP) - EURAMOS-1 did not show any benefit to the addition of IE; however, certain centers still do so (i.e., MD Anderson...